Adalimumab for the Treatment of Non-Infectious Uveitis: A Real Life Experience

ObjectiveTo describe the efficacy and safety of adalimumab for the treatment of non-infectious uveitis (NIU) in four Uveitis Units from tertiary Spanish hospitals. MethodsMulticenter and retrospective clinical cohort study including all patients with NIU treated with adalimumab from January 2012 to...

Descripción completa

Detalles Bibliográficos
Autores: Raad, Fatima, Luque, Paula, Garcia Ledo, Sofia, Alda Lozano, Alicia, Llorens Bellés, Víctor, Espejo, Antonio, Heras, Henar, Santana, Lucia, Trapiella, Luis, Fanlo, Patricia, Adán Civera, Alfredo, Espinosa Garriga, Gerard, Navarrete, Nuria
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2024
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/216867
Acceso en línea:https://hdl.handle.net/2445/216867
Access Level:acceso abierto
Palabra clave:Uveïtis
Anticossos monoclonals
Terapèutica
Uveitis
Monoclonal antibodies
Therapeutics
id ES_f784412bc91e9d7d4a4b7c08b2e2ee99
oai_identifier_str oai:recercat.cat:2445/216867
network_acronym_str ES
network_name_str España
repository_id_str
spelling Adalimumab for the Treatment of Non-Infectious Uveitis: A Real Life ExperienceRaad, FatimaLuque, PaulaGarcia Ledo, SofiaAlda Lozano, AliciaLlorens Bellés, VíctorEspejo, AntonioHeras, HenarSantana, LuciaTrapiella, LuisFanlo, PatriciaAdán Civera, AlfredoEspinosa Garriga, GerardNavarrete, NuriaUveïtisAnticossos monoclonalsTerapèuticaUveitisMonoclonal antibodiesTherapeuticsObjectiveTo describe the efficacy and safety of adalimumab for the treatment of non-infectious uveitis (NIU) in four Uveitis Units from tertiary Spanish hospitals. MethodsMulticenter and retrospective clinical cohort study including all patients with NIU treated with adalimumab from January 2012 to October 2022 in four uveitis units was performed. Efficacy was measured with the number of relapses, ocular inflammation and reduction in immunosuppression and corticosteroid dosage before and after adalimumab use. We collected data regarding adverse effects and examined the immunogenicity of adalimumab. ResultsOne hundred and twenty-two patients (59% females), with a mean age of 48.6 years (SD = 14.8) accounting for 217 eyes were included. The majority (92.6%) were Caucasian. Uveitis analyzed were predominantly panuveitis (34.7%), bilateral (77.9%), acute (41.5%), and non-granulomatous (90%). Most of them were immune mediated (42.6%), and the main reason to initiate adalimumab was refractory disease (96.7%). The analysis was statistically significant due to the reduction in the number of immunosuppressive drugs as well as the dose of oral corticosteroids and the number of relapses during follow-up (p < 0.001). The decrease in ocular inflammation parameters and the improvement in visual acuity (p < 0.05) were also significant. There were no deaths due to the drug and only one reported case of serious infection. In total, 10.9% of 73 patients tested developed anti-adalimumab antibodies and 4.1% lupus-like. ConclusionsWe consider adalimumab as a leading drug in the treatment of NIU with high safety and efficacy.Taylor and Francis2024202520242024info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersion23 p.application/pdfapplication/pdfhttps://hdl.handle.net/2445/216867Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésVersió postprint del document publicat a: https://doi.org/10.1080/09273948.2024.2344712Ocular Immunology And Inflammation, 2024, p.1-7https://doi.org/10.1080/09273948.2024.2344712(c) Taylor and Francis, 2024info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2168672026-05-29T05:05:01Z
dc.title.none.fl_str_mv Adalimumab for the Treatment of Non-Infectious Uveitis: A Real Life Experience
title Adalimumab for the Treatment of Non-Infectious Uveitis: A Real Life Experience
spellingShingle Adalimumab for the Treatment of Non-Infectious Uveitis: A Real Life Experience
Raad, Fatima
Uveïtis
Anticossos monoclonals
Terapèutica
Uveitis
Monoclonal antibodies
Therapeutics
title_short Adalimumab for the Treatment of Non-Infectious Uveitis: A Real Life Experience
title_full Adalimumab for the Treatment of Non-Infectious Uveitis: A Real Life Experience
title_fullStr Adalimumab for the Treatment of Non-Infectious Uveitis: A Real Life Experience
title_full_unstemmed Adalimumab for the Treatment of Non-Infectious Uveitis: A Real Life Experience
title_sort Adalimumab for the Treatment of Non-Infectious Uveitis: A Real Life Experience
dc.creator.none.fl_str_mv Raad, Fatima
Luque, Paula
Garcia Ledo, Sofia
Alda Lozano, Alicia
Llorens Bellés, Víctor
Espejo, Antonio
Heras, Henar
Santana, Lucia
Trapiella, Luis
Fanlo, Patricia
Adán Civera, Alfredo
Espinosa Garriga, Gerard
Navarrete, Nuria
author Raad, Fatima
author_facet Raad, Fatima
Luque, Paula
Garcia Ledo, Sofia
Alda Lozano, Alicia
Llorens Bellés, Víctor
Espejo, Antonio
Heras, Henar
Santana, Lucia
Trapiella, Luis
Fanlo, Patricia
Adán Civera, Alfredo
Espinosa Garriga, Gerard
Navarrete, Nuria
author_role author
author2 Luque, Paula
Garcia Ledo, Sofia
Alda Lozano, Alicia
Llorens Bellés, Víctor
Espejo, Antonio
Heras, Henar
Santana, Lucia
Trapiella, Luis
Fanlo, Patricia
Adán Civera, Alfredo
Espinosa Garriga, Gerard
Navarrete, Nuria
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Uveïtis
Anticossos monoclonals
Terapèutica
Uveitis
Monoclonal antibodies
Therapeutics
topic Uveïtis
Anticossos monoclonals
Terapèutica
Uveitis
Monoclonal antibodies
Therapeutics
description ObjectiveTo describe the efficacy and safety of adalimumab for the treatment of non-infectious uveitis (NIU) in four Uveitis Units from tertiary Spanish hospitals. MethodsMulticenter and retrospective clinical cohort study including all patients with NIU treated with adalimumab from January 2012 to October 2022 in four uveitis units was performed. Efficacy was measured with the number of relapses, ocular inflammation and reduction in immunosuppression and corticosteroid dosage before and after adalimumab use. We collected data regarding adverse effects and examined the immunogenicity of adalimumab. ResultsOne hundred and twenty-two patients (59% females), with a mean age of 48.6 years (SD = 14.8) accounting for 217 eyes were included. The majority (92.6%) were Caucasian. Uveitis analyzed were predominantly panuveitis (34.7%), bilateral (77.9%), acute (41.5%), and non-granulomatous (90%). Most of them were immune mediated (42.6%), and the main reason to initiate adalimumab was refractory disease (96.7%). The analysis was statistically significant due to the reduction in the number of immunosuppressive drugs as well as the dose of oral corticosteroids and the number of relapses during follow-up (p < 0.001). The decrease in ocular inflammation parameters and the improvement in visual acuity (p < 0.05) were also significant. There were no deaths due to the drug and only one reported case of serious infection. In total, 10.9% of 73 patients tested developed anti-adalimumab antibodies and 4.1% lupus-like. ConclusionsWe consider adalimumab as a leading drug in the treatment of NIU with high safety and efficacy.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024
2024
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/216867
url https://hdl.handle.net/2445/216867
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: https://doi.org/10.1080/09273948.2024.2344712
Ocular Immunology And Inflammation, 2024, p.1-7
https://doi.org/10.1080/09273948.2024.2344712
dc.rights.none.fl_str_mv (c) Taylor and Francis, 2024
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) Taylor and Francis, 2024
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 23 p.
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor and Francis
publisher.none.fl_str_mv Taylor and Francis
dc.source.none.fl_str_mv Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424890303479808
score 15.811543

Similares en LA Referencia